جست‌وجوی استاد و پژوهشگر

Kristian Helinمشاهده پروفایل

استاد

• Cancer biology
• Epigenetics
• Stem cells
• +۵ مورد دیگر

Kristian Helin is Chief Executive and President of The Institute of Cancer Research (ICR), London, and a Professor with affiliations at the University of Copenhagen and Memorial Sloan Kettering Cancer Center. He founded/directed the Biotech Research & Innovation Centre (BRIC), Centre for Epigenetics, and Danish Stem Cell Center. His research focuses on epigenetic regulation, cancer biology, and stem cell differentiation. Education: Ph.D. Molecular Biology, University of Copenhagen (1991) M.Sc. Chemical Engineering, Technical University of Denmark (1988) Research Interests: Helin's work deciphers molecular mechanisms in cancer, emphasizing epigenetic drivers (e.g., H3K4/H3K36 methylation), transcriptional control, and therapeutic targeting. His lab identified E2F transcription factors, linked epigenetic dysregulation to leukemia/lymphoma, and develops drugs targeting kinases/epigenetic enzymes. Research spans acute myeloid leukemia, B-cell lymphoma, and solid tumors using CRISPR screens and preclinical models. Publication Trends: Recent articles (2023-2025) focus on epigenetic therapy, chromatin remodeling, and kinase signaling in cancer. Key themes include targeting NSD1/KDM5C/RIOK2 enzymes, combination therapies (EZH2/DOT1L inhibitors), and metabolic regulation in leukemia. Studies bridge basic mechanisms (enhancer regulation, insulator accessibility) with translational applications. Awards: Anders Jahre Prize (2014), ERC Advanced Grant (2011), Novo Nordisk Prize (2008) Memberships: Academia Europaea, Royal Danish Academy, EMBO Leadership: Helin co-founded EpiTherapeutics (acquired by Gilead) and leads the Epigenetics and Cancer lab at ICR. His team investigates AML pathogenesis and chromatin complexes like HUSH/NURF. Grants include ERC funding and innovation prizes.

Sheng Liمشاهده پروفایل

دانشیار

• Cancer Epigenetics
• Aging
• Clonal Hematopoiesis
• +۳ مورد دیگر

Sheng Li is an Associate Professor of Cancer Biology at the University of Southern California's Keck School of Medicine. She co-leads the Epigenetic Regulation in Cancer Program at the Norris Comprehensive Cancer Center. Her research integrates multi-omics and computational approaches to study epigenetic heterogeneity in blood cancers, aging, and clonal hematopoiesis. Her lab focuses on single-cell spatial multi-omics, 3D epigenomics, and long-read sequencing to map epigenetic drivers of leukemogenesis. Awards include the Leukemia & Lymphoma Society Scholar Award and AACR NextGen Star recognition. She mentors PhD students and postdocs, with her team publishing extensively in high-impact journals. Her publications demonstrate a strong emphasis on computational epigenetics, cancer systems biology, and geroscience. Recent work includes developing tools for spatial transcriptomics interpretation and modeling IDH-mutant AML gene networks.

Dean Tantinمشاهده پروفایل

استاد

• Gene regulation in T cells
• T cell memory and autoimmunity
• Stem cell biology
• +۴ مورد دیگر

Dean Tantin is a Professor of Microbiology and Immunology at the University of Utah School of Medicine, where his research delves into gene regulation in T cells, stem cells, and cancer. His lab investigates how transcription factors like Oct1, Oct4, and OCA-B control stem-like properties in cells, impacting immunological memory, autoimmunity, and cancer progression. Education: B.S. – University of California, San Diego Ph.D. – University of California, Los Angeles Research Interests: Dr. Tantin’s work centers on understanding how transcription factors regulate cell fate decisions, particularly in T cells and stem cells. His lab explores the roles of Oct1 and Oct4 in pluripotency and differentiation, the function of OCA-B in T cell memory and autoimmunity, and the therapeutic potential of targeting these factors in diseases like multiple sclerosis and type 1 diabetes. A major focus is on how these transcription factors control gene expression programs that endow cells with longevity, self-renewal, and rapid response capabilities. Article Trends: Recent publications highlight a strong emphasis on transcriptional regulation in immune cells, particularly CD4+ T cells, and stem cells. Studies explore how OCA-B and Oct factors influence T cell memory formation, autoimmune responses, and cancer development. The work bridges molecular mechanisms with translational applications, including potential drug targets for autoimmune diseases and cancer. Laboratory and Team: Dr. Tantin leads an active research group at the University of Utah, supported by training grants and core facilities. His lab employs molecular biology, genomics, and in vivo models to dissect transcriptional networks. While specific student names are not listed, his mentorship is evident through his involvement in bioscience PhD programs and collaborative projects.

Emek Demirمشاهده پروفایل

دانشیار

• Computational Biology
• Cancer Bioinformatics
• Pathway Informatics
• +۵ مورد دیگر

Emek Demir serves as an Associate Professor in the Department of Molecular and Medical Genetics at Oregon Health & Science University's School of Medicine, where he directs the Computational Biology program at the Brenden-Colson Center for Pancreatic Care. His academic journey includes a Ph.D. in Computer Engineering from Bilkent University (2005) under Ugur Dogrusoz and postdoctoral training with Chris Sander at Memorial Sloan Kettering Cancer Center's Computational Biology Center. Dr. Demir's research centers on Pathway Informatics, integrating detailed biological pathway information with omic data to solve cancer biology problems. His work spans pathway curation, visualization, NLP, data standardization, machine learning, and mechanistic simulation. He pioneered the BioPAX pathway data standard and developed Pathway Commons—the largest process-level pathway database with over 2 million interactions and 400,000 detailed human reactions. His publication record demonstrates consistent innovation in computational oncology, with recent work focusing on transcription factor activity prediction, spatial tumor mapping, and causal network analysis. Key contributions include algorithms for detecting altered cancer sub-networks, identifying transcription factor modulators, and inferring active networks from proteomic data. His research bridges computational methods with clinical applications in leukemia, prostate cancer, and glioblastoma. Recipient of leadership roles in major NIH-funded initiatives Principal developer of Pathway Commons and BioPAX standards Extensive collaborations with Memorial Sloan Kettering and OHSU clinical departments Dr. Demir directs a computational biology program focused on translating pathway knowledge into clinical insights for pancreatic cancer, with ongoing projects in spatial omics, multi-dimensional tumor atlases, and antiviral nanomaterial applications.

Stephen J. Formanمشاهده پروفایل

استاد

• Hematology
• Oncology
• Bone Marrow Transplantation
• +۷ مورد دیگر

Stephen J. Forman, M.D. is a Professor in the Department of Hematology & Hematopoietic Cell Transplantation and Department of Medical Oncology & Therapeutics Research at City of Hope Comprehensive Cancer Center. He serves as Director of the Hematologic Malignancies Research Institute, Principal Investigator of the Lymphoma SPORE, and Director of the T Cell Therapeutics Research Laboratory. Dr. Forman has dedicated over 45 years to advancing treatments for blood cancers and has been instrumental in dramatically improving survival rates for patients with hematologic malignancies. Dr. Forman earned his M.D. from the University of Southern California in 1974 and a B.A. in Philosophy from St. John's College in 1970. His medical training includes residency and internship at Harbor UCLA Hospital, fellowship in Hematology at LAC+USC Medical Center, and fellowship in Medical Oncology at City of Hope. Dr. Forman is an international expert in leukemia, lymphoma, and bone marrow transplantation. His research focuses on immunotherapy, particularly using T cells for cancer treatment. He has been deeply involved with translational and clinical research at City of Hope's Toni Stephenson Lymphoma Center, Cellular Immunotherapy Center, Judy and Bernard Briskin Center for Multiple Myeloma Research, and the Gehr Family Center for Leukemia Research. His work in CAR T-cell therapy has positioned him at the forefront of cellular immunotherapy for hematologic malignancies. Analysis of Dr. Forman's recent publications reveals a strong focus on advancing T cell immunotherapy, particularly CAR T-cell approaches for hematologic malignancies. His research spans from basic mechanisms of T cell function to clinical applications in leukemia, lymphoma, and myeloma. A significant portion of his work addresses challenges in immunotherapy, including antigen escape, treatment resistance, and improving the safety profile of cellular therapies. His research demonstrates a clear trajectory from laboratory discoveries to clinical implementation, reflecting his commitment to translational medicine. E. Donnall Thomas Lecture, American Society for Blood and Marrow Transplantation (2019) DKMS Mechtild Harf Science Award (2019) Dr. Forman has been a principal investigator on numerous research grants, including the Lymphoma SPORE (Specialized Programs of Research Excellence), which represents significant NIH funding for lymphoma research. As Director of the Hematologic Malignancies Research Institute and former Chair of the Department of Hematology & Hematopoietic Cell Transplantation, he has overseen extensive research programs and mentored countless clinicians and scientists. His leadership in the field is reflected in his co-editorship of "Thomas' Hematopoietic Cell Transplantation," considered the definitive textbook in the field. Dr. Forman directs the T Cell Therapeutics Research Laboratory at the Beckman Research Institute of City of Hope, where his team investigates novel approaches to harness the immune system against cancer. He is also co-leader of the Hematologic Malignancies Program within City of Hope's Comprehensive Cancer Center, coordinating a multidisciplinary team focused on improving outcomes for patients with blood cancers. His work bridges basic science and clinical application, with a particular emphasis on translating laboratory discoveries into effective treatments for patients.

Erika Tsingosمشاهده پروفایل

استادیار

• Computational Biology
• Animal Developmental Biology
• Multiscale Modeling
• +۴ مورد دیگر

Dr. Erika Tsingos serves as an Assistant Professor in the Department of Theoretical Biology and Bioinformatics at Utrecht University's Faculty of Science. She leads the Computational Animal Development Group focusing on computational approaches to developmental biology questions. Her research spans animal developmental biology with emphasis on Computer modeling of cell fate decisions Pattern formation in tissues Cell migration mechanics Thymus development and leukemogenesis C. elegans developmental precision She employs diverse modeling approaches including ordinary differential equations and multiscale cell-based models using cellular Potts or center-based formalisms. Analysis of her 15 most recent publications reveals strong focus on computational modeling of developmental processes, particularly examining extracellular matrix effects on cell migration, thymic niche architecture in leukemia development, and precise cell fate specification in C. elegans. Her work consistently bridges computational modeling with experimental validation through collaborations. Scientific recognition includes: NWO grant VI.Veni.222.323 for research on extracellular matrix effects on cell migration Dr. Tsingos actively mentors the next generation of computational biologists through supervision of postdoctoral researchers and students. Current team members include Benjamin Planterose Jiménez (post-doc modeling C. elegans development), Saber Shakibi (post-doc developing hybrid migration models), and Nikki Landzaat (Master's student studying mesoderm cell state transitions). Former students include Bidayatul Masulah (Master's in Applied Mathematics) and Heleen van Osch (bachelor researcher). Her research group operates within Utrecht University's Department of Theoretical Biology and Bioinformatics, collaborating extensively with the Ten Tusscher group and experimental labs. Current projects investigate how extracellular matrix affects cell migration phenotypes in cancer and the molecular control mechanisms behind C. elegans' precise cell division patterns.

• Medical Genetics
• Cytogenetics
• Oncology
• +۴ مورد دیگر

Susan B. Olson is a Professor in the Department of Medical Genetics at Oregon Health & Science University's School of Medicine. With over three decades of experience since earning her Ph.D. in Medical Genetics in 1987, she has established herself as a leading researcher in cytogenetics and molecular genetics, particularly focusing on Fanconi anemia and hematologic malignancies. Her work bridges basic science with clinical applications, contributing significantly to our understanding of genetic disorders and cancer mechanisms. Dr. Olson's research interests center on the molecular mechanisms of Fanconi anemia, acute myeloid leukemia, and other genetic disorders. Her laboratory investigates DNA repair pathways, particularly the Fanconi anemia pathway, and how defects in these processes lead to bone marrow failure and cancer predisposition. She has made significant contributions to understanding NUP98 rearrangements in leukemia, RUNX1 mutations, and the role of FANCD2 in DNA replication through fragile sites. Her work often combines cytogenetic analysis with molecular techniques to uncover novel mechanisms underlying genetic diseases. Analysis of Dr. Olson's recent publications (2016-2024) reveals a consistent focus on genetic mechanisms in cancer and inherited disorders. Her research spans from basic molecular studies of DNA repair mechanisms to clinical investigations of leukemia and lymphoma. A significant portion of her work centers on Fanconi anemia pathophysiology, with applications to understanding cancer development. She frequently employs advanced techniques including single-cell and spatial transcriptomics, cytogenetic analysis, and molecular diagnostics to address fundamental questions in medical genetics. Throughout her career, Dr. Olson has maintained productive collaborations with clinicians and researchers across multiple institutions, particularly with Stephen R. Moore at Oregon Health & Science University. Her work has been supported by various research grants focused on understanding the molecular basis of genetic disorders and developing potential therapeutic approaches, particularly for Fanconi anemia and acute myeloid leukemia.

David Wiestمشاهده پروفایل

استاد

• T lymphocyte development
• Immunodeficiency
• Hematopoiesis
• +۱۲ مورد دیگر

David Wiest is a Professor and the Scientific Director of the Research Institute at Fox Chase Cancer Center, affiliated with the Center for Immunology and the Nuclear Dynamics and Cancer (NDC) program. He leads a dynamic research laboratory focused on understanding the molecular mechanisms of T lymphocyte development, transformation, and immunodeficiency, with significant implications for cancer therapy. Dr. Wiest earned his PhD in Immunology from Duke University in 1991 and completed postdoctoral training in Developmental Immunology at the National Institutes of Health (NIH), finishing in 1995. His career has been dedicated to advancing knowledge in immunology and cancer biology through innovative research. His research interests center on the specification of αβ and γδ T cell lineages, the regulatory functions of ribosomal proteins like Rpl22 in hematopoiesis and leukemogenesis, the use of zebrafish models to identify disease-causing genes in immunodeficient humans, and the role of ERK2 substrate binding domains in cancer. His lab employs genome-wide approaches to uncover fundamental insights into immune cell development and applies this knowledge to improve cancer treatments. The lab's work spans from basic molecular mechanisms to translational applications, including developing anti-cancer immune effectors and novel therapeutic strategies for myeloproliferative disorders. His recent publications (2021–2025) reflect a strong focus on immune cell development, cancer signaling pathways (especially Ras/MAPK and STING), ribosomal protein functions, and the genetic basis of immunodeficiencies. Key themes include the role of transcription factors (TCF1, E proteins, Egr2) in cell fate decisions, metabolic regulation in leukemia, and the use of zebrafish for disease modeling and xenotransplantation studies. Dr. Wiest has been recognized with numerous scientific awards, including: American Cancer Society Southeastern Pennsylvania Research Award Norman F. Conant Award for Excellence in Research Election to the Henry Kunkel Society Cancer Research Institute Fellow NCI Board of Scientific Counselors Senior Research Excellence Award Bucks County Board of Associates Key to the Chapter Award Inspired Leadership Award He actively mentors students and postdoctoral fellows, including graduate student Billy Truong from Temple University, and collaborates with national and international researchers. His lab is a hub of scientific inquiry, with ongoing projects that integrate genetics, molecular biology, and immunology to address critical questions in cancer and immune disorders. The Wiest lab investigates how ribosomal proteins like Rpl22 and its paralog Rpl22-Like1 regulate hematopoietic stem cell potential and transformation, and how ERK2 domains can be targeted therapeutically in cancers with Ras/MAPK activation. The lab also uses zebrafish models to screen for human disease-causing mutations and study tumor xenotransplantation, contributing to both basic science and clinical applications.

• Computational Biology
• Bioinformatics
• Gene Regulation
• +۴ مورد دیگر

Lihua Julie Zhu is a Professor and the head of Bioinformatics Core in the Department of Molecular, Cell and Cancer Biology at UMass Chan Medical School (UMMS). She also holds positions in the T.H. Chan School of Medicine, Program in Molecular Medicine, Interdisciplinary Graduate Program, and Bioinformatics and Integrative Biology program. With an interdisciplinary background spanning nutritional sciences and computer science, Dr. Zhu leads a research program focused on computational biology and bioinformatics methodologies for genomic data analysis. Dr. Zhu's educational background includes: BS in Animal Nutrition from China Agricultural University, Beijing MS in Animal Nutrition from China Agricultural University, Beijing MS in Computer Science from DePaul University, Chicago PhD in Nutritional Sciences from University of Wisconsin-Madison Dr. Zhu's research focuses on understanding gene regulation and cancer etiology through the development and application of computational tools for analyzing high-throughput genomic datasets. Her lab specializes in mining and integrating various genomic technologies including WGS, ChIP-seq, bulk and single cell RNA-seq, and ATAC-seq. A key strength of her research program is algorithm development, with her team having created over 20 computational tools, including numerous Bioconductor packages that serve the broader research community. Analysis of Dr. Zhu's recent publications (2024-2025) reveals a strong emphasis on both methodological innovation and biological discovery. Her work spans cancer biology, genome editing technologies, and computational tool development across multiple biological systems. A significant portion of her recent publications involve the creation of specialized bioinformatics tools for analyzing complex genomic datasets, demonstrating her dual commitment to advancing computational methodology while making biological discoveries. Dr. Zhu leads the Bioinformatics Core facility at UMass Chan Medical School, providing essential computational expertise and support to researchers across the institution. The core facility plays a critical role in enabling sophisticated genomic analyses for numerous research projects requiring advanced computational approaches to analyze complex biological data.

Rahul Kohliمشاهده پروفایل

دانشیار

• DNA Modifying Enzymes
• Epigenetics
• Antibiotic Resistance
• +۶ مورد دیگر

Rahul Kohli, M.D., Ph.D. is Associate Professor of Medicine and Biochemistry & Biophysics at the University of Pennsylvania's Perelman School of Medicine, Department of Medicine. His laboratory is located in Johnson Pavilion at 3610 Hamilton Walk, Philadelphia, PA. Dr. Kohli's research focuses on DNA modifying enzymes that add complexity to the genome through purposeful mutation and nucleobase modification. His work spans two primary areas: (1) enzymatic deamination, oxidation and methylation of cytosine bases with emphasis on AID/APOBEC DNA deaminases and TET oxygenases; and (2) targeting pathogen pathways that promote evolution and antibiotic resistance, particularly the LexA/RecA axis governing the bacterial SOS response. His lab employs biochemical characterization of enzyme mechanisms, chemical synthesis of enzyme probes, and biological assays spanning bacteriology, immunology, and virology. Analysis of Dr. Kohli's recent publications reveals a strong emphasis on developing novel epigenetic sequencing technologies, understanding TET enzyme mechanisms in cancer and development, engineering hyperactive DNA modifying enzymes for genome editing applications, and targeting bacterial stress responses to combat antibiotic resistance. His work bridges chemical biology, epigenetics, and infectious disease research. Scientific Awards: Benjamin Franklin Medal in Chemistry (2017) Dr. Kohli mentors a robust research team with 15 lab members including graduate students and undergraduate researchers. His work has been supported by multiple grants focused on DNA modification enzymes and their applications in epigenetics and antimicrobial resistance. His research has significant implications for cancer therapy, genome editing technologies, and novel antibiotic development strategies. The Kohli laboratory maintains active collaborations across multiple disciplines, particularly in immunology and cancer research, as evidenced by publications related to CAR-T cell therapy where TET2 disruption enhances therapeutic efficacy.

Tarik Möröyمشاهده پروفایل

استاد پژوهشی

• Molecular Biology
• Immunology
• Hematology
• +۷ مورد دیگر

Dr. Tarik Möröy is a Full Research Professor at the Faculty of Medicine of the Université de Montréal and serves as the President and Scientific Director of the Montreal Clinical Research Institute (IRCM). He is a leading expert in molecular biology, immunology, and cancer research, with over 180 publications, an h-index of 66, and 13,500+ citations. His work focuses on the transcriptional and epigenetic regulation of hematopoiesis and its role in immune system malignancies. Education Ph.D. in Biochemistry, University of Ludwig-Maximilians, Munich (1987) Postdoctoral Researcher, Columbia University, New York (1988–1991) Research Interests Dr. Möröy investigates the molecular mechanisms of immune cell differentiation and leukemogenesis, emphasizing transcription factors (GFI1, GFI1B, c-Myc, Miz-1), RNA helicases (DDX3X), and long non-coding RNAs (lncRNA). His lab combines multiplex flow cytometry, genomics, and computational biology to model hematopoietic malignancies. Publication Trends Recent work explores GFI1/PRMT1 interactions in DNA repair, DDX3X in lymphoid differentiation, and lncRNAs in leukemia. Themes include transcriptional regulation, epigenetic mechanisms, and RNA biology in hematopoietic cancers. Scientific Awards Canada Research Chair (Tier 1) in Hematopoiesis and Immune Cell Differentiation (2007–2021) IRC Medal of Merit for Exceptional Service (2019) Elected member of the Canadian Academy of Health Sciences (2018) Advising and Leadership Dr. Möröy has mentored doctoral students like Marion Lacroix and leads a multidisciplinary team at the IRCM. He has served on national and international scientific advisory boards, including Recherche Canada (President since 2023) and the Canadian Society for Molecular Biosciences (President 2018–2020).

Janice Telferمشاهده پروفایل

استاد

• Immunology
• Hematopoiesis
• Transcription Factor Regulation
• +۵ مورد دیگر

Janice Telfer is a Professor in the Department of Veterinary and Animal Sciences at the University of Massachusetts Amherst. She serves as Undergraduate Program Director and UMass Pre-Veterinary Medicine Advisor. Her research focuses on the role of RUNX family transcription factors in immune system development, particularly their influence on hematopoietic stem cells and leukemogenesis. She also investigates WC1 co-receptor function in bovine gamma delta T cells and the structural biology of SRCR domains. Telfer holds a Ph.D. from Harvard University (1995) and completed postdoctoral training at the California Institute of Technology. Her lab explores mechanisms linking transcriptional regulation to immune cell differentiation and cancer predisposition. She teaches courses in cellular/molecular biology, veterinary terminology, and immunology. Education: Ph.D., Harvard University, 1995 Postdoctoral Training: California Institute of Technology Affiliations: Director of Undergraduate Programs, Pre-Vet Advisor Research Interests: Her work integrates molecular, cellular, and structural approaches to study immune system regulation. Key areas include RUNX1's role in myeloid leukemogenesis, WC1 receptor signaling in bovine immunity, and structural characterization of SRCR domains involved in microbial recognition. Her lab uses retroviral expression systems and molecular modeling to investigate transcription factor networks and receptor-ligand interactions. Publications: Recent work includes studies on CD163 family evolution, WC1-mediated T-cell proliferation, and SRCR domain structure-function relationships. These investigations bridge basic immunology with veterinary medicine applications.

• Cancer Genomics
• Epigenetics
• Bioinformatics
• +۲ مورد دیگر

Timothy J Triche is Professor of Pathology at the Keck School of Medicine, University of Southern California. He directs research in cancer genomics, epigenetics, and bioinformatics, with emphasis on pediatric malignancies. His laboratory develops computational tools for genomic analysis and focuses on translating molecular discoveries into clinical diagnostics. Research spans pediatric acute myeloid leukemia, prostate cancer, and sarcoma biology, integrating multi-omics approaches. Key interests include liquid biopsy development, epigenetic dysregulation, and gene fusion mechanisms in oncogenesis. Publications demonstrate consistent focus on molecular diagnostics and bioinformatic innovation, with recent work advancing single-cell analysis methodologies and non-invasive cancer profiling. Earlier foundational studies established mechanisms of fusion oncoproteins in sarcomas.

Bradley R. Cairnsمشاهده پروفایل

استاد

• Chromatin Remodeling
• Germline Development
• Transcription Regulation
• +۷ مورد دیگر

Bradley R. Cairns, PhD, is Professor and Chair of the Department of Oncological Sciences at the University of Utah School of Medicine, Chief Academic Officer of the Huntsman Cancer Institute (HCI), and holder of the Jon M. Huntsman Presidential Endowed Chair in Cancer Research. His research focuses on chromatin remodeling, germline development, and cancer mechanisms, utilizing zebrafish, yeast, and human models. Dr. Cairns pioneered the purification of chromatin remodeling complexes (SWI/SNF, RSC) and revealed their dysregulation in cancer. Education: PhD in Cell Biology, Stanford University (1996) BS (Honors) in Chemistry, Lewis and Clark College (1987) Postdoctoral training at Harvard Medical School and Stanford University Research Interests: Dr. Cairns investigates how chromatin structure regulates gene expression in germline stem cells and early embryos, with emphasis on totipotency establishment. His lab studies: 1) Mechanisms of nucleosome remodeling by ATP-dependent complexes; 2) Epigenetic poising of developmental genes in sperm; 3) Single-cell dynamics of human spermatogenesis; and 4) DUX transcription factors in embryonic genome activation. Key models include zebrafish embryogenesis and human testis development. Publication Trends: Recent work emphasizes single-cell genomics of human germline development, 3D chromatin architecture in embryogenesis, and p53-mediated regulation in muscular dystrophy. Studies consistently integrate biochemical, genetic, and genomic approaches to dissect chromatin-transcription relationships in development and disease. Awards & Honors: Fellow, Royal Society (2023) American Academy of Arts and Sciences (2017) Howard Hughes Medical Institute Investigator (2000–present) Leukemia Society Fellowship American Cancer Society Fellowship Leadership & Training: Dr. Cairns has mentored 26 graduate students and 12 postdoctoral fellows. He directs the Molecular Biology Graduate Program and co-leads HCI’s Nuclear Control Program. Administrative roles include chairing HCI’s Bioinformatics and Genomics Cores and co-chairing the Commission on Equity, Diversity, and Inclusion. Lab & Collaborations: The Cairns Lab employs biochemical, genomic, and genetic methods to study chromatin dynamics. Key collaborations include the Human Testis Atlas project and studies on FSHD muscular dystrophy. Lab resources include protocols for chromatin profiling and zebrafish embryogenesis.

Karla Rodgersمشاهده پروفایل

استاد

• Immunology
• Molecular Biology
• Genetics
• +۳ مورد دیگر

Dr. Karla Rodgers is a Professor in the Department of Microbiology and Immunology at the University of Oklahoma Health Sciences Center. Her research focuses on understanding mechanisms regulating V(D)J recombination and its role in adaptive immunity. She holds a PhD from the University of Illinois, Urbana-Champaign, and has prior research experience at Yale University. Her research interests include: Molecular basis of antigen receptor gene diversification RAG1/RAG2 protein complex regulation DNA repair mechanisms during lymphocyte development Genetic defects causing immunodeficiency Her lab uses advanced techniques such as high-throughput recombination assays to study recombination signal sequence (RSS) specificity and investigates nuclear dynamics of RAG proteins under DNA damage conditions. Current lab personnel include graduate students Justin Harris and Cooper McKinney, and research technician John Ngo. Notable research directions include: Quantitative analysis of RSS sequence determinants DDR pathway interactions with V(D)J recombination Risk assessment of off-target RAG activity in leukemogenesis Dr. Rodgers has maintained an NIH-funded research program for over 15 years, with publications in leading journals such as Nucleic Acids Research and Immunobiology . Her work bridges basic immunology with clinical implications for immunodeficiency and cancer.